OncoMatch/Clinical Trials/NCT07291297

Metformin Hydrochloride in Combination With Standard of Care Systemic Therapy in Previously Untreated Advanced Unresectable or Metastatic Soft Tissue Sarcoma

Is NCT07291297 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Metformin Hydrochloride ER for sarcoma metastatic.

Phase 2RecruitingWake Forest University Health SciencesNCT07291297Data as of May 2026

Treatment: Metformin Hydrochloride ER — The purpose of this research study is to see how metformin, when used in combination with standard of care (SOC) treatment for metastatic (cancer that has spread) soft tissue sarcoma can improve patient outcomes.

Check if I qualify

Extracted eligibility criteria

Cancer type

Sarcoma

Disease stage

Required: Stage IV, INTERMEDIATE, HIGH GRADE

Metastatic disease required

advanced unresectable or metastatic/intermediate/high grade soft tissue sarcoma

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Min 0 prior lines

Cannot have received: metformin (metformin)

Already prescribed and taking metformin at time of diagnosis of advanced unresectable or metastatic disease

Cannot have received: investigational drug

Treatment with any investigational drug within 14 days prior to day 1 of treatment

Lab requirements

Kidney function

adequate renal function

Liver function

adequate liver function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

Levine Cancer Institute · Charlotte, North Carolina
Atrium Health Wake Forest Baptist Comprehensive Cancer Center · Winston-Salem, North Carolina

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify